Pharmaceuticals

Global Cyclosporine Market Overview: Trends Shaping Growth to 2029

November 10, 2025November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Cyclosporine Industry In 2025?

The cyclosporine market size has witnessed significant expansion in recent years. It is anticipated to increase from $2.65 billion in 2024 to $2.98 billion in 2025, at a compound annual growth rate (CAGR) of 12.6%. This historical growth can be attributed to the rising count of organ transplants, an increase in autoimmune conditions, the prevalence of chronic diseases, a surge in kidney disorders, and the broadening of transplant centers.

The cyclosporine market size is anticipated to experience substantial growth over the coming years. This market is projected to reach $4.85 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.9%. This projected growth during the forecast period stems from factors such as an increase in organ donations, wider adoption of immunotherapy, a growing elderly patient population, an expanding specialty pharmaceutical sector, and a higher prevalence of rheumatoid arthritis. Key developments expected in the forecast period encompass the creation of new immunosuppressive treatments, advancements in AI-driven drug development, progress in nanotechnology integration, innovations involving blockchain in the drug supply chain, and improvements in drug delivery methods.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23360&type=smp

Which Major Market Drivers Are Shaping The Future Of The Cyclosporine Market?

An increasing occurrence of autoimmune diseases is anticipated to boost the expansion of the cyclosporine market in the future. These diseases are characterized by the immune system erroneously targeting the body’s healthy cells, leading to inflammation, cellular harm, and persistent sickness. The increased frequency of autoimmune conditions is linked to genetic susceptibility, given that developments in genetic screening have pinpointed more people with inherited predispositions, rendering them more vulnerable. Cyclosporine demonstrates efficacy in managing autoimmune diseases by inhibiting T-cell activation, consequently diminishing detrimental immune reactions against healthy tissues in ailments like rheumatoid arthritis, psoriasis, and lupus. To illustrate, in May 2024, a report from the National Institutes of Health (NIH), a US-based government entity, indicated that in 2022, psoriatic arthritis (PsA) had a prevalence of 0.221% and an incidence rate of 13.54 per 100,000 people. Consequently, the expanding occurrence of autoimmune diseases is stimulating the growth of the cyclosporine market.

What Are The Major Segment Types Covered In The Cyclosporine Market?

The cyclosporine market covered in this report is segmented –

1) By Indication: Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye, Other Indications

2) By Dosage Form: Capsule, Eye Drops, Liquid Solutions, Creams And Ointments

3) By Route Of Administration: Oral, Topical, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Homecare, Speciality Centres, Other End-Users

Subsegments:

1) By Transplant Rejection Prophylaxis: Kidney Transplant, Liver Transplant, Heart Transplant, Lung Transplant, Other Transplants

2) By Rheumatoid Arthritis: Moderate Rheumatoid Arthritis, Severe Rheumatoid Arthritis

3) By Psoriasis: Plaque Psoriasis, Erythrodermic Psoriasis, Guttate Psoriasis, Pustular Psoriasis

4) By Autoimmune Myasthenia Gravis: Generalized Myasthenia Gravis, Ocular Myasthenia Gravis

5) By Dry Eye: Chronic Dry Eye, Severe Dry Eye

6) By Other Indications: Atopic Dermatitis, Uveitis, Nephrotic Syndrome, Inflammatory Bowel Disease (IBD)

What Trends Are Redefining The Cyclosporine Market Dynamics?

Key players in the cyclosporine market are concentrating on securing regulatory clearances to expand their product ranges and strengthen their market standing. Such approvals for cyclosporine confirm its safety and effectiveness, thereby facilitating market entry and boosting confidence among both prescribers and patients. For example, in June 2023, Novaliq GmbH, a biopharmaceutical firm based in Germany, obtained approval from the U.S. FDA for VEVYE (cyclosporine ophthalmic solution) 0.1%, an exclusive water-free ophthalmic medication formulated for treating dry eye disease (DED). This is the initial and only cyclosporine-based solution for this condition, showing effectiveness within just four weeks. VEVYE incorporates an innovative water-free technology known as EyeSol, which enhances cyclosporine’s bioavailability and residence time on the ocular surface, free from preservatives, oils, or surfactants. The solution acts as a calcineurin inhibitor, aiding in the reduction of inflammation connected to dry eye disease.

Which Key Players Are Driving Competition In The Cyclosporine Market?

Major companies operating in the cyclosporine market are Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Apotex Inc., Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Lupin Limited, Glenmark Pharmaceuticals Ltd, Taj Pharmaceuticals Limited, Panacea Biotec Ltd, Novaliq GmbH, Simson Pharma Limited, Strides Pharma Science Ltd, AdvaCare Pharma, JoinHub Pharma, Grevis Pharmaceuticals Pvt Ltd, GMT Pharma International, Logos Pharma.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cyclosporine-global-market-report

What Regional Growth Trends Are Shaping The Cyclosporine Market Outlook?

Asia-Pacific was the largest region in the cyclosporine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the cyclosporine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cyclosporine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23360&type=smp

Browse Through More Reports Similar to the Global Cyclosporine Market 2025, By The Business Research Company

Connected Drug Delivery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/connected-drug-delivery-devices-global-market-report

Controlled Release Drug Delivery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Covid19 Drug Associated Api Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795